COSCIENS Biopharma Inc. (formerly Aeterna Zentaris Inc.) (NASDAQ:
AEZS) (TSX: AEZS) ("COSCIENS" or the "Company"), a specialty
biopharmaceutical company developing and commercializing a
diversified portfolio of pharmaceutical and diagnostic products and
active ingredients for healthcare and cosmetics industries, today
announces that the Company’s name has been changed from “Aeterna
Zentaris Inc.” to “COSCIENS Biopharma Inc.”, effective as of August
6, 2024 (the “Name Change”).
In addition, the Company announces that,
effective as of August 9, 2024, the Company’s common shares (the
“Common Shares”) will begin trading on the Toronto Stock Exchange
(the “TSX”) and NASDAQ Capital Market (the “NASDAQ”) under the
trading symbol “CSCI” and will concurrently cease trading thereon
under the former trading symbol “AEZS”.
At the Company’s annual general and special
meeting of shareholders held on July 16, 2024, the shareholders of
the Company approved a special resolution authorizing the board of
directors of the Company to effect the Name Change. Implementation
of the Name Change remains subject to the final approval of the TSX
and the NASDAQ.
There is no change in the capitalization of the
Company in connection with the Name Change and no action will be
required by existing shareholders or warrantholders of COSCIENS in
connection with the Name Change. Certificates representing Common
Shares and warrants of the Company (the “Warrants”) will not be
affected by the Name Change and will not need to be exchanged. The
Company encourages any shareholder or warrantholder with any
questions or concerns to contact the Company or to discuss any of
the foregoing with their broker or agent.
The new CUSIP number for the Common Shares is
22112H101, and the new ISIN for the Common Shares is CA22112H1010.
In addition, the new CUSIP number for the Warrants is 22112H119,
and the new ISIN for the Warrants is CA22112H1192.
About COSCIENS Biopharma Inc.
COSCIENS is a specialty biopharmaceutical
company engaged in the development and commercialization of a
diverse portfolio of pharmaceutical and diagnostic products,
including those focused on areas of significant unmet medical need.
One of COSCIENS’ lead products is macimorelin (Macrilen;
Ghryvelin), the first and only U.S. FDA and European Commission
approved oral test indicated for the diagnosis of adult growth
hormone deficiency (AGHD). COSCIENS is also engaged in the
development of therapeutic assets and proprietary extraction
technology, which is applied to the production of active
ingredients from renewable plant resources currently used in
cosmeceutical products (i.e., oat beta glucan and avenanthramides
which are found in leading skincare product brands like Aveeno and
Burt’s Bees formulations) and being developed as potential
nutraceuticals and/or pharmaceuticals.
The Company is listed on the NASDAQ and the TSX,
and currently trades on both exchanges under the ticker symbol
“AEZS” (however, as noted above, the Company will begin trading on
such exchanges under the ticker symbol “CSCI” effective as of
August 9, 2024). For more information, please visit COSCIENS’
website at www.zentaris.com.
Forward-Looking Statements
The information in this news release has been
prepared as of August 6, 2024. Certain statements in this news
release, referred to herein as "forward-looking statements",
constitute "forward-looking statements" within the meaning of the
United States Private Securities Litigation Reform Act of 1995, as
amended, and "forward-looking information" under the provisions of
Canadian securities laws. All statements, other than statements of
historical fact, that address circumstances, events, activities, or
developments that could or may or will occur are forward-looking
statements. When used in this news release, words such as
"anticipate", "assume", "believe", "could", "expect", "forecast",
"future", "goal", "guidance", "intend", "likely", "may", "would" or
the negative or comparable terminology as well as terms usually
used in the future and the conditional are generally intended to
identify forward-looking statements, although not all
forward-looking statements include such words. Forward-looking
statements in this news release include, but are not limited to,
statements relating to the Name Change, including the final
approval of the Name Change for trading purposes by the TSX and the
NASDAQ and the trading of the Common Shares on the TSX and NASDAQ
under the trading symbol “CSCI” and concurrent cessation of trading
under the trading symbol “AEZS”.
Forward-looking statements are necessarily based
upon a number of factors and assumptions that, while considered
reasonable by the Company as of the date of such statements, are
inherently subject to significant business, economic, operational
and other risks, uncertainties, contingencies and other factors,
including those described below, which could cause actual results,
performance or achievements of the combined Company to be
materially different from results, performance or achievements
expressed or implied by such forward-looking statements and, as
such, undue reliance must not be placed on them.
Forward-looking statements involve known and
unknown risks and uncertainties which include, among others: the
combined Company’s present and future business strategies;
operations and performance within expected ranges; anticipated
future cash flows; local and global economic conditions and the
environment in which the combined Company operates; anticipated
capital and operating costs; uncertainty in product development and
related clinical trials and validation studies, including our
reliance on the success of the pediatric clinical trial in the
European Union and U.S. for Macrilen™ (macimorelin); the result of
the DETECT-trial may not support receipt of regulatory approval in
child-onset growth hormone deficiency; results from ongoing or
planned pre-clinical studies of macimorelin by the University of
Queensland or for our other products under development may not be
successful or may not support advancing the product to human
clinical trials; our ability to raise capital and obtain financing
to continue our currently planned operations; our now heavy
dependence on the success of Macrilen™ (macimorelin) and related
out-licensing arrangements and the continued availability of funds
and resources to successfully commercialize the product; the
ability to secure strategic partners for late stage development,
marketing, and distribution of our products, including our ability
to enter into a new license agreement or similar arrangement
following the termination of the license agreement with Novo
Nordisk AG; our ability to enter into out-licensing, development,
manufacturing, marketing and distribution agreements with other
pharmaceutical companies and keep such agreements in effect; our
ability to protect and enforce our patent portfolio and
intellectual property; and our ability to continue to list our
Common Shares on the NASDAQ.
Investors should consult our quarterly and
annual filings with the Canadian and U.S. securities commissions
for additional information on risks and uncertainties, including
those discussed in our Annual Report on Form 20-F and MD&A
filed under the Company’s profile on SEDAR+ at www.sedarplus.ca and
on EDGAR at www.sec.gov. We disclaim any obligation to update any
such risks or uncertainties or to publicly announce any revisions
to any of the forward-looking statements contained herein to
reflect future results, events or developments, unless required to
do so by a governmental authority or applicable law.
No securities regulatory authority has either
approved or disapproved of the contents of this news release. The
Toronto Stock Exchange accepts no responsibility for the adequacy
or accuracy of this news release.
Investor Contact:
Jenene ThomasJTC TeamT: +1 (833) 475-8247E: aezs@jtcir.com
Aeterna Zentaris (NASDAQ:AEZS)
過去 株価チャート
から 8 2024 まで 9 2024
Aeterna Zentaris (NASDAQ:AEZS)
過去 株価チャート
から 9 2023 まで 9 2024